drugset / Trial / NCT06537297
Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases
NaSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed with high-dose Furmonertinib plus bevacizumab for EGFR-mutant non-small cell lung cancer patients with leptomeningeal metastases after resistance to third-generation EGFR-TKIs.
Timeline
- Start
- 2024-09-30
- Primary completion
- 2025-08-31
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Firmonertinib | Small molecule | 160 mg | — |
| Subject | Pemetrexed | Small molecule | 50 mg | Intrathecal |